In 2023, Croatia led European antacid sales with $2.4 per capita, experiencing a 3.71% decrease. In contrast, Greece saw a 3.71% uptick. Luxembourg and Portugal faced notable declines, with -5.59% and -6.51%, respectively. Italy, Slovenia, Czech Republic, and Latvia showed no change year-over-year. These variations highlight diverse market dynamics within the region, with Croatia maintaining the highest per capita consumption despite its drop, and Greece marking marginal growth amidst relatively low sales values.
Looking ahead, economic conditions, healthcare policies, and demographic shifts will influence market dynamics. Growing health awareness and the aging European population may drive overall demand, while innovation in product formulations and distribution channels could alter individual country sales trajectories.
Top countries in Antacid Medicine Sales by Country
| # | 8 Countries | US Dollars Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Croatia | 2.4 | 2023 | -4% | -3.71% | View data |
| 2 | 2 Greece | 0.6 | 2023 | 0% | +3.71% | View data |
| 3 | 3 Luxembourg | 0.6 | 2023 | 0% | -5.59% | View data |
| 4 | 4 Italy | 0.5 | 2023 | -16.67% | 0% | View data |
| 5 | 5 Slovenia | 0.5 | 2023 | 0% | 0% | View data |
| 6 | 6 Portugal | 0.5 | 2023 | 0% | -6.51% | View data |
| 7 | 7 Czech Republic | 0.4 | 2023 | +33.33% | 0% | View data |
| 8 | 8 Latvia | 0.3 | 2023 | -25% | 0% | View data |
